Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nicorandil→

Nicorandil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
65141-46-0
Molecular formula
C8H9N3O4
Molecular weight
211.18 g/mol
Drug class
Potassium-channel opener and nitrate-like vasodilatorantianginal agent
Mechanism of action
Opens ATP-sensitive potassium channels in vascular smooth muscle and also provides nitrate-like nitric oxide activity, producing arterial and venous vasodilation and reducing myocardial oxygen demand while improving coronary blood flow.
Indications / reported uses
  • Prevention and long-term symptomatic treatment of stable angina pectoris in adults when first-line antianginal therapies are inadequate or unsuitable in countries where nicorandil is authorised; not for treatment of acute angina attacks

Sources: NHS — Nicorandil · EMA — Nicorandil safety review · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nicorandil Environmental Risk Assessment (ERA) (the Nicorandil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.